210 related articles for article (PubMed ID: 35017100)
1. Association between sodium glucose co-transporter 2 inhibitors and incident glaucoma in patients with type 2 diabetes: A multi-institutional cohort study in Taiwan.
Shao SC; Su YC; Lai EC; Chang KC; Lee CN; Hung MJ; Lai CC; Huang FC; Hung JH
Diabetes Metab; 2022 Jan; 48(1):101318. PubMed ID: 35017100
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan.
Su YC; Hung JH; Chang KC; Sun CC; Huang YH; Lee CN; Hung MJ; Lai CC; Shao SC; Lai EC
JAMA Netw Open; 2022 Sep; 5(9):e2232584. PubMed ID: 36136333
[TBL] [Abstract][Full Text] [Related]
3. Risk of diabetic macular oedema with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients: A multi-institutional cohort study in Taiwan.
Su YC; Shao SC; Lai EC; Lee CN; Hung MJ; Lai CC; Hsu SM; Hung JH
Diabetes Obes Metab; 2021 Sep; 23(9):2067-2076. PubMed ID: 34047442
[TBL] [Abstract][Full Text] [Related]
4. Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD.
Hu JC; Shao SC; Tsai DH; Chuang AT; Liu KH; Lai EC
JAMA Netw Open; 2024 Mar; 7(3):e240946. PubMed ID: 38436955
[TBL] [Abstract][Full Text] [Related]
5. The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.
Ueda P; Wintzell V; Dahlqwist E; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Melbye M; Hviid A; Svanström H; Pasternak B
Diabetes Obes Metab; 2022 Mar; 24(3):473-485. PubMed ID: 34738703
[TBL] [Abstract][Full Text] [Related]
6. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
[TBL] [Abstract][Full Text] [Related]
7. Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.
Lim CE; Pasternak B; Eliasson B; Danaei G; Ueda P
Eur J Prev Cardiol; 2023 Jun; 30(8):634-643. PubMed ID: 36582120
[TBL] [Abstract][Full Text] [Related]
8. Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan.
Chung MC; Hung PH; Hsiao PJ; Wu LY; Chang CH; Wu MJ; Shieh JJ; Chung CJ
JAMA Netw Open; 2021 Nov; 4(11):e2135353. PubMed ID: 34797368
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease.
Luo J; Feldman R; Callaway Kim K; Rothenberger S; Korytkowski M; Hernandez I; Gellad WF
JAMA Netw Open; 2023 Jun; 6(6):e2317886. PubMed ID: 37307000
[TBL] [Abstract][Full Text] [Related]
10. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.
Baviera M; Genovese S; Lepore V; Colacioppo P; Robusto F; Tettamanti M; D'Ettorre A; Avanzini F; Fortino I; Nicolucci A; Roncaglioni MC; Giorgino F
Diabetes Obes Metab; 2021 Jul; 23(7):1484-1495. PubMed ID: 33606897
[TBL] [Abstract][Full Text] [Related]
11. Major adverse limb events in type 2 diabetes patients receiving glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A retrospective multi-institutional study.
Hsiao FC; Lin CP; Tung YC; Wu CT; Chu PH
Diabetes Res Clin Pract; 2021 Oct; 180():109076. PubMed ID: 34599973
[TBL] [Abstract][Full Text] [Related]
12. Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.
Fralick M; Chen SK; Patorno E; Kim SC
Ann Intern Med; 2020 Feb; 172(3):186-194. PubMed ID: 31931526
[TBL] [Abstract][Full Text] [Related]
13. Sodium-Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study.
Engström A; Wintzell V; Melbye M; Hviid A; Eliasson B; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Pasternak B; Ueda P
Diabetes Care; 2023 Feb; 46(2):351-360. PubMed ID: 36508322
[TBL] [Abstract][Full Text] [Related]
14. GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.
Neves JS; Borges-Canha M; Vasques-Nóvoa F; Green JB; Leiter LA; Granger CB; Carvalho D; Leite-Moreira A; Hernandez AF; Del Prato S; McMurray JJV; Ferreira JP
J Am Coll Cardiol; 2023 Aug; 82(6):517-525. PubMed ID: 37532422
[TBL] [Abstract][Full Text] [Related]
15. Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study.
Alkabbani W; Zongo A; Minhas-Sandhu JK; Eurich DT; Shah BR; Alsabbagh MW; Gamble JM
Can J Diabetes; 2022 Jun; 46(4):392-403.e13. PubMed ID: 35513988
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care.
Fralick M; Schneeweiss S; Redelmeier DA; Razak F; Gomes T; Patorno E
Diabetes Obes Metab; 2021 Oct; 23(10):2320-2328. PubMed ID: 34169619
[TBL] [Abstract][Full Text] [Related]
17. SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study.
Al-Mashhadi ZK; Viggers R; Starup-Linde J; Vestergaard P; Gregersen S
Front Endocrinol (Lausanne); 2022; 13():861422. PubMed ID: 36060970
[TBL] [Abstract][Full Text] [Related]
18. Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
Lin TY; Kang EY; Shao SC; Lai EC; Garg SJ; Chen KJ; Kang JH; Wu WC; Lai CC; Hwang YS
Diabetes Metab J; 2023 May; 47(3):394-404. PubMed ID: 36872060
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus.
Fralick M; Colacci M; Thiruchelvam D; Gomes T; Redelmeier DA
Diabetes Obes Metab; 2021 Apr; 23(4):950-960. PubMed ID: 33336894
[TBL] [Abstract][Full Text] [Related]
20. The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study.
Werkman NCC; Driessen JHM; Stehouwer CDA; Vestergaard P; Schaper NC; van den Bergh JP; Nielen JTH
Cardiovasc Diabetol; 2023 Jun; 22(1):160. PubMed ID: 37386427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]